{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:11:45Z","timestamp":1770750705703,"version":"3.50.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1007\/s11906-003-0056-3","type":"journal-article","created":{"date-parts":[[2007,8,29]],"date-time":"2007-08-29T08:29:19Z","timestamp":1188376159000},"page":"486-492","source":"Crossref","is-referenced-by-count":14,"title":["Management of hypertension emergencies"],"prefix":"10.1007","volume":"5","author":[{"given":"William J.","family":"Elliott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"56_CR1","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al.: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). JAMA 2003, 289:2560\u20132572. This is the most current report of the US Expert Panel on hypertension. The EXPRESS version of the report includes only a few words about hypertensive emergencies.","journal-title":"JAMA"},{"key":"56_CR2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jama.1991.03470060091033","volume":"266","author":"RW Gifford Jr","year":"1991","unstructured":"Gifford RW Jr: Management of hypertensive crises. JAMA 1991, 266:829\u2013835.","journal-title":"JAMA"},{"key":"56_CR3","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(94)90696-3","volume":"344","author":"NM Kaplan","year":"1994","unstructured":"Kaplan NM: Management of hypertensive emergencies. Lancet 1994, 344:1335\u20131338.","journal-title":"Lancet"},{"key":"56_CR4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1378\/chest.118.1.214","volume":"118","author":"J Varon","year":"2000","unstructured":"Varon J, Marik PE: The diagnosis and management of hypertensive crises. Chest 2000, 118:214\u2013227.","journal-title":"Chest"},{"key":"56_CR5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0749-0704(05)70176-7","volume":"17","author":"WJ Elliott","year":"2001","unstructured":"Elliott WJ: Hypertensive emergencies. Crit Care Clin 2001, 17:435\u2013451. A recent overview of hypertensive emergencies that reaches conclusions similar to those found in this chapter.","journal-title":"Crit Care Clin"},{"key":"56_CR6","volume-title":"The Kidney and Hypertension","author":"WJ Elliott","year":"2003","unstructured":"Elliott WJ: Hypertensive urgencies. In The Kidney and Hypertension. Edited by Bakris GL. London: Martin Dunitz Publishers; 2003, In press. A recent overview of hypertensive urgencies, focusing more on the various available treatment options than on the distinction between urgencies and emergencies."},{"key":"56_CR7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/bmj.292.6515.235","volume":"292","author":"MEK Ahmed","year":"1986","unstructured":"Ahmed MEK, Walker JM, Beevers DG, Beevers M: Lack of difference between malignant and accelerated hypertension. BMJ 1986, 292:235\u2013237.","journal-title":"BMJ"},{"key":"56_CR8","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/00004872-199508000-00013","volume":"13","author":"GYH Lip","year":"1995","unstructured":"Lip GYH, Beevers M, Beevers DG: Complications and survival in 315 patients with malignant-phase hypertension. J Hypertens 1995, 13:915\u2013924.","journal-title":"J Hypertens"},{"key":"56_CR9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archinte.1928.00130140003001","volume":"41","author":"NM Keith","year":"1928","unstructured":"Keith NM, Wagener HP, Kernohan JW: The syndrome of malignant hypertension. Arch Intern Med 1928, 41:141\u2013153.","journal-title":"Arch Intern Med"},{"key":"56_CR10","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1067\/mhj.2002.111542","volume":"144","author":"DC Felmeden","year":"2002","unstructured":"Felmeden DC, Beevers DG, Yip GYH: Tackling malignant hypertension: not so desperate now [letter]. Am Heart J 2002, 144:E4.","journal-title":"Am Heart J"},{"key":"56_CR11","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/ndt\/11.7.1261","volume":"11","author":"P Kumar","year":"1996","unstructured":"Kumar P, Arora P, Kher V, et al.: Malignant hypertension in children in India. Nephrol Dial Transplant 1996, 11:1261\u20131266.","journal-title":"Nephrol Dial Transplant"},{"key":"56_CR12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000006954","volume":"92","author":"JJ Lima De","year":"1999","unstructured":"De Lima JJ, da Fonseca JA, Godoy A, et al.: Outcome of patients with malignant hypertension and end-stage renal failure treated by long-term hemodialysis. Cardiology 1999, 92:93\u201398.","journal-title":"Cardiology"},{"key":"56_CR13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/sj.jhh.1000963","volume":"14","author":"S Kadiri","year":"2000","unstructured":"Kadiri S, Olutade BO, Osobamiro O: Factors influencing the development of malignant hypertension in Nigeria. J Hum Hypertens 2000, 14:171\u2013174.","journal-title":"J Hum Hypertens"},{"key":"56_CR14","first-page":"303","volume":"92","author":"S Kadiri","year":"2002","unstructured":"Kadiri S, Thomas JO: Focal segmental glomerulosclerosis in malignant hypertension. S Afr Med J 2002, 92:303\u2013305.","journal-title":"S Afr Med J"},{"key":"56_CR15","first-page":"19","volume":"7","author":"JF Sung","year":"1997","unstructured":"Sung JF, Harris-Hooker S, Alema-Mensah E, Mayberry R: Is there a difference in hypertensive claim rates among Medicaid recipients? Ethn Dis 1997, 7:19\u201326.","journal-title":"Ethn Dis"},{"key":"56_CR16","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1056\/NEJM199209103271107","volume":"327","author":"S Shea","year":"1992","unstructured":"Shea S, Misra D, Francis CK: Predisposing factors for severe, uncontrolled hypertension in an inner-city minority population. N Engl J Med 1992, 327:776\u2013781.","journal-title":"N Engl J Med"},{"key":"56_CR17","first-page":"581","volume":"7","author":"I Balazovjech","year":"1993","unstructured":"Balazovjech I, Hnilica P Jr: Compliance with antihypertensive treatment in consultation rooms for hypertensive patients. J Human Hypertens 1993, 7:581\u2013583.","journal-title":"J Human Hypertens"},{"key":"56_CR18","first-page":"969","volume":"146","author":"CA Wijman","year":"2002","unstructured":"Wijman CA, Beijer IS, van Dijk GW, et al.: Hypertensive encephalopathy: does not only occur at high blood pressure (in Dutch). Ned Tijdsch Geneeskunde 2002, 146:969\u2013973.","journal-title":"Ned Tijdsch Geneeskunde"},{"key":"56_CR19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1291\/hypres.25.467","volume":"25","author":"K Eguchi","year":"2002","unstructured":"Eguchi K, Kasahara K, Nagashima A, et al.: Two cases of malignant hypertension with reversible diffuse leukoencephalopathy exhibiting a reversible nocturnal blood pressure \"riser\" pattern. Hypertens Res Clin Exp 2002, 25:467\u2013473.","journal-title":"Hypertens Res Clin Exp"},{"key":"56_CR20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/qjmed\/90.9.571","volume":"90","author":"GY Lip","year":"1997","unstructured":"Lip GY, Beevers M, Beevers DG: Malignant hypertension in young women is related to previous hypertension in pregnancy, not oral contraception. QJM 1997, 90:571\u2013575.","journal-title":"QJM"},{"key":"56_CR21","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3109\/08037059609079679","volume":"5","author":"J Zarifis","year":"1996","unstructured":"Zarifis J, Lip GY, Leatherdale B, Beevers G: Malignant hypertension in association with primary hyperaldosteronism. Blood Press 1996, 5:250\u2013254.","journal-title":"Blood Press"},{"key":"56_CR22","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2169\/internalmedicine.36.700","volume":"36","author":"K Oka","year":"1997","unstructured":"Oka K, Hayashi K, Nakazato T, et al.: Malignant hypertension in a patient with primary hyperaldosteronism with elevated active renin concentration. Intern Med 1997, 36:700\u2013704.","journal-title":"Intern Med"},{"key":"56_CR23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/qjmed\/95.2.128","volume":"95","author":"H Suzuki","year":"2002","unstructured":"Suzuki H, Asano K, Eiro M, et al.: Recovery from renal failure in malignant hypertension associated with primary aldosteronism: effect of an ACE-inhibitor. QJM 2002, 95:128\u2013130.","journal-title":"QJM"},{"key":"56_CR24","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S0895-7061(01)02245-2","volume":"14","author":"JD Blumenfeld","year":"2001","unstructured":"Blumenfeld JD, Laragh JH: Management of hypertensive crises: the scientific basis for treatment decisions. Am J Hypertens 2001, 14:1154\u20131167.","journal-title":"Am J Hypertens"},{"key":"56_CR25","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2169\/internalmedicine.41.566","volume":"41","author":"T Nagai","year":"2002","unstructured":"Nagai T, Imamura M, Misumi S, Mori M: Subclinical Cushing\u2019s disease accompanied by malignant hypertension and diabetes mellitus. Intern Med 2002, 41:566\u2013570.","journal-title":"Intern Med"},{"key":"56_CR26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1081\/CEH-100104237","volume":"23","author":"C Guerrera","year":"2001","unstructured":"Guerrera C, Colivicchi F, Pola R, et al.: Acute abdominal symptoms in malignant hypertension: clinical presentation in five cases. Clin Exp Hypertens 2001, 23:461\u2013469.","journal-title":"Clin Exp Hypertens"},{"key":"56_CR27","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.2169\/naika.91.2473","volume":"91","author":"S Fukase","year":"2002","unstructured":"Fukase S, Suzuki M, Goto T, et al.: IgA nephropathy with malignant hypertension (in Japanese). Nippon Naika Gakkai Zasshi 2002, 91:2473\u20132475.","journal-title":"Nippon Naika Gakkai Zasshi"},{"key":"56_CR28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/qjmed\/94.6.327","volume":"94","author":"E Edmunds","year":"2001","unstructured":"Edmunds E, Landray MJ, Li-Saw-Hee FL, et al.: Dyslipidaemia in patients with malignant-phase hypertension. QJM 2001, 94:327\u2013332.","journal-title":"QJM"},{"key":"56_CR29","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0895-7061(01)02045-3","volume":"14","author":"GY Lip","year":"2001","unstructured":"Lip GY, Edmunds E, Hee FL, et al.: A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension. Am J Hypertens 2001, 14:823\u2013828.","journal-title":"Am J Hypertens"},{"key":"56_CR30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.jhh.1001386","volume":"16","author":"GY Lip","year":"2002","unstructured":"Lip GY, Edmunds E, Nuttall SL, et al.: Oxidative stress in malignant and nonmalignant phase hypertension. J Hum Hypertens 2002, 16:333\u2013336.","journal-title":"J Hum Hypertens"},{"key":"56_CR31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1291\/hypres.22.61","volume":"22","author":"J Kato","year":"1999","unstructured":"Kato J, Kitamura K, Matsui E, et al.: Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. Hypertens Res 1999, 22:61\u201365.","journal-title":"Hypertens Res"},{"key":"56_CR32","first-page":"439","volume":"53","author":"CG Isles","year":"1984","unstructured":"Isles CG, McLay A, Boulton Jones JM: Recovery in malignant hypertension presenting as acute renal failure. QJM 1984, 53:439\u2013458.","journal-title":"QJM"},{"key":"56_CR33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0002-9343(86)90005-7","volume":"80","author":"AA Bakir","year":"1986","unstructured":"Bakir AA, Bazilinski N, Dunea G: Transient and sustained recovery from renal shutdown in accelerated hypertension. Am J Med 1986, 80:172\u2013176.","journal-title":"Am J Med"},{"key":"56_CR34","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1177\/089686080102100608","volume":"21","author":"IJ Katz","year":"2001","unstructured":"Katz IJ, Sofianou L, Butler O, Hopley M: Recovery of renal function in Black South African patients with malignant hypertension: superiority of continuous ambulatory peritoneal dialysis over hemodialysis. Perit Dial Int 2001, 21:581\u2013586. The most recently-published experience showing that recovery of renal function after a hypertensive emergency is possible; this paper indicates that more people recover from peritoneal dialysis than from hemodialysis.","journal-title":"Perit Dial Int"},{"key":"56_CR35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/adc.85.5.401","volume":"85","author":"AC Browning","year":"2001","unstructured":"Browning AC, Mengher LS, Gregson RM, Amoaku WM: Visual outcome of malignant hypertension in young people. Arch Dis Child 2001, 85:401\u2013403.","journal-title":"Arch Dis Child"},{"key":"56_CR36","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200009073431007","volume":"343","author":"T Brott","year":"2000","unstructured":"Brott T, Bogousslavsky J: Drug therapy: treatment of acute ischemic stroke. N Engl J Med 2000, 343:710\u2013722. Asserts that there is no evidence that lowering BP in the setting of an acute stroke is beneficial, and some evidence that it might be harmful.","journal-title":"N Engl J Med"},{"key":"56_CR37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00002018-199819020-00003","volume":"19","author":"E Grossman","year":"1998","unstructured":"Grossman E, Ironi AN, Messerli FH: Comparative tolerability profile of hypertensive crisis treatments. Drug Safety 1998, 19:99\u2013122. A useful overview of the tolerability of drugs useful in hypertensive emergencies, suggesting that there are few important differences among the commonly used drugs.","journal-title":"Drug Safety"},{"key":"56_CR38","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1001\/jama.1996.03540160050032","volume":"276","author":"E Grossman","year":"1996","unstructured":"Grossman E, Messerli FH, Grodzicki T, Kowey P: Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996, 276:1328\u20131331.","journal-title":"JAMA"},{"key":"56_CR39","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jama.1996.03540160064035","volume":"276","author":"MA Winker","year":"1996","unstructured":"Winker MA: The FDA\u2019s decisions regarding new indications for approved drugs. Where\u2019s the evidence? [editorial]. JAMA 1996, 276:1342\u20131343.","journal-title":"JAMA"},{"key":"56_CR40","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJMra010253","volume":"345","author":"MB Murphy","year":"2001","unstructured":"Murphy MB, Murray C, Shorten GD: Fenoldopam: a selective peripheral dopamine-receptor agonist for treatment of severe hypertension. N Engl J Med 2001, 345:1548\u20131557. An excellent review of the pharmacology and uses of this dopamine-1 receptor agonist, which has been reasonably well-studied in hypertensive emergencies, but which might have broader utility in other therapeutic areas.","journal-title":"N Engl J Med"},{"key":"56_CR41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0002-9343(93)90256-O","volume":"95","author":"NH Shusterman","year":"1993","unstructured":"Shusterman NH, Elliott WJ, White WB: Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with normal or impaired baseline renal function. Am J Med 1993, 95:161\u2013168.","journal-title":"Am J Med"},{"key":"56_CR42","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1553-2712.2000.tb02039.x","volume":"7","author":"JA Tumlin","year":"2000","unstructured":"Tumlin JA, Dunbar LM, Oparil S, et al.: Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial. Fenoldopam Study Group. Acad Emerg Med 2000, 7:653\u2013662. The most recent multicenter clinical trial experience with fenoldopam mesylate in the setting of hypertensive emergencies.","journal-title":"Acad Emerg Med"},{"key":"56_CR43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/jop.1998.14.203","volume":"14","author":"JR Piltz","year":"1998","unstructured":"Piltz JR, Stone RA, Boike S, et al.: Fenoldopam, a selective dopamine-1 receptor agonist, raises intraocular pressure in males with normal intraocular pressure. J Ocul Pharmacol Ther 1998, 14:203\u2013216. This protocol was performed to verify a previous study of intraocular pressure measurements in patients with hypertensive emergencies, which showed that fenoldopam infusion was associated with a dose-dependent increase in intraocular pressure. This also was seen in normotensive people in this report.","journal-title":"J Ocul Pharmacol Ther"},{"key":"56_CR44","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/00000542-199908000-00032","volume":"91","author":"ZA Copper","year":"1999","unstructured":"Copper ZA, Mihm FG: Blood pressure control with fenoldopam during excision of a pheochromocytoma. Anesthesiology 1999, 91:558\u2013560.","journal-title":"Anesthesiology"},{"key":"56_CR45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00045391-199909000-00007","volume":"6","author":"LM Strauser","year":"1999","unstructured":"Strauser LM, Pruitt RD, Tobias JD: Initial experience with fenoldopam in children. Am J Ther 1999, 6:283\u2013288.","journal-title":"Am J Ther"},{"key":"56_CR46","doi-asserted-by":"crossref","unstructured":"Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000, 183:S1\u2013S22. Unlike many other intravenously administered drugs (eg, sodium nitroprusside), fenoldopam mesylate might be particularly useful during pregnancy; it is one of a very few drugs to be rated category B in pregnancy by the US Food and Drug Administration.","DOI":"10.1067\/mob.2000.107928"},{"key":"56_CR47","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1067\/mhj.2002.122118","volume":"143","author":"JA Tumlin","year":"2002","unstructured":"Tumlin JA, Wang A, Murray PT, Mathur VS: Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention ofcontrast nephropathy. Am Heart J 2002, 143:894\u2013903. This study is being followed by a large-scale, randomized, clinical trial, the results of which (if positive) could greatly increase the utility of this drug beyond hypertensive emergencies.","journal-title":"Am Heart J"},{"key":"56_CR48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/107424840100600104","volume":"6","author":"TB Gilbert","year":"2001","unstructured":"Gilbert TB, Hasnain JU, Flinn WR, et al.: Fenoldopam infusion associated with preserving renal function after aortic cross-clamping for aneurysm repair. J Cardiovasc Pharmacol Ther 2001, 6:31\u201336. Larger studies that might validate the impressive results seen in this study are now nearing completion.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"56_CR49","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/jcan.2001.20374","volume":"15","author":"M Halpenny","year":"2001","unstructured":"Halpenny M, Lakshmi S, O\u2019Donnell A, et al.: The effects of fenoldopam on coronary conduit blood flow after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2001, 15:72\u201376. Larger studies are now nearing completion that might validate the rather impressive results seen in this study. This might be the clinical situation for which fenoldopam has the greatest utility a decade from now.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"56_CR50","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1017\/S0265021502000054","volume":"19","author":"M Halpenny","year":"2002","unstructured":"Halpenny M, Rushe C, Breen P, et al.: The effects of fenoldopam on renal function in patients undergoing electiv aortic surgery. Eur J Anaesthesiol 2002, 19:32\u201339. Larger studies are now nearing completion that might validate the promising results seen in this study.","journal-title":"Eur J Anaesthesiol"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-003-0056-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-003-0056-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-003-0056-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T05:45:17Z","timestamp":1587879917000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-003-0056-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["56"],"URL":"https:\/\/doi.org\/10.1007\/s11906-003-0056-3","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}